Condition

Melanoma (3)

Advanced Melanoma (1)

Metastatic Melanoma (1)

Metastatic Prostate Adenocarcinoma (1)

Stage IV Prostate Cancer AJCC v8 (1)

Unresectable Melanoma (1)

Overall Status

Active, not recruiting (2)

Available (1)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 2 (2)

phase 1 (1)

phase 2/phase 3 (1)

Sponsor

Regeneron Pharmaceuticals (3)

Diwakar Davar (1)

Emory University (1)

Collaborator

Bristol-Myers Squibb (1)

CellSight Technologies, Inc. (1)

Checkmate Pharmaceuticals (1)

National Cancer Institute (NCI) (1)

Prostate Cancer Foundation (1)

Intervention

nivolumab (3)

cmp-001 (2)

[18f]f-arag pet/ct (1)

pembrolizumab (1)

vidutolimod (1)

vidutolimod (cmp-001) (1)

vlp-encapsulated tlr9 agonist cmp-001, (1)

Study Documents

Intervention Type

drug (5)

biological (2)

other (1)

Funder Type

Industry (3)

Other (2)

Study Type

Interventional (4)

Expanded Access (1)

vidutolimod

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Trial (Vidutolimod)

Available

Vidutolimod

(no location specified)

Sep 25, 2023

Melanoma Trial in Pittsburgh (drug, biological, other)

Recruiting

Melanoma

Vidutolimod (CMP-001)
+2 more

Pittsburgh, Pennsylvania

UPMC Hillman Cancer Center

Mar 25, 2022

Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Atlanta (VLP-encapsulated TLR9 Agonist CMP-001,,

Not yet recruiting

Metastatic Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8

VLP-encapsulated TLR9 Agonist CMP-001,
Nivolumab

Atlanta, Georgia

Emory University Hospital/Winship Cancer Institute

Aug 26, 2022

Melanoma, Advanced Melanoma, Metastatic Melanoma Trial in United States (CMP-001, Nivolumab)

Active, not recruiting

Melanoma
+3 more

Phoenix, Arizona
+19 more

Aug 1, 2022

Melanoma Trial in United States (CMP-001, Pembrolizumab)

Active, not recruiting

Melanoma

Phoenix, Arizona
+12 more

Aug 1, 2022